Grace Therapeutics (GRCE) Stock Price, News & Analysis

Company Overview

Grace Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare and debilitating diseases with significant unmet medical needs. The company uses proprietary drug-delivery technologies to develop alternative formulations intended to improve the administration, tolerability, or effectiveness of existing pharmaceutical compounds.

Its pipeline has included GTX-102, an investigational formulation of betamethasone being developed for ataxia-telangiectasia, a rare inherited disorder, and GTX-104, an investigational intravenous formulation of nimodipine intended for patients at risk of complications following aneurysmal subarachnoid hemorrhage. The company’s development programs are subject to clinical testing and regulatory review, and their ultimate availability is not assured.

Grace Therapeutics is headquartered in the United States and has focused its operations on advancing therapies for patients with rare diseases. Information about its commercial operations and broader geographic presence remains limited because the company is primarily development-stage rather than an established commercial pharmaceutical business.

Key Stats

• Today's Range: $2.00 to $2.07
• 50-Day Range: $2.04 to $2.33
• 52-Week Range: $1.79 to $5.18
• Volume: 35,123 shs
• Average Volume: 382,033 shs
• Market Capitalization: $42.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Grace Therapeutics Stock Analysis - MarketRank™

Grace Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 644th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Grace Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Grace Therapeutics has a consensus price target of $6.00, representing about 195.6% upside from its current price of $2.03.

Amount of Analyst Coverage

Grace Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Grace Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Grace Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Grace Therapeutics has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.41% of the float of Grace Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Grace Therapeutics has a short interest ratio ("days to cover") of 8.56.

Change versus previous month

Short interest in Grace Therapeutics has recently increased by 11.30%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Grace Therapeutics does not currently pay a dividend.

Dividend Growth

Grace Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for GRCE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Grace Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Grace Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.84% of the stock of Grace Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

6.08% of the stock of Grace Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:GRCE
• Previous Symbol: NASDAQ:GRCE
• CIK: 1444192
• Web: www.gracetx.com
• Phone: (609) 322-1602
• Fax: 45-0687-2272
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Grace Therapeutics: $6.00
• High Price Target: $8.00
• Low Price Target: $4.00
• Potential Upside/Downside: +192.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -36.11%
• Return on Assets: -34.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.47
• Quick Ratio: 11.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.99 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 21,040,000
• Free Float: 18,756,000
• Market Cap: $43.22 million
• Optionable: N/A
• Beta: 0.33